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physical examinations. Under-diagnosis for PAD in prac-
tice was common and it might have under-estimated PAD
prevalence.
CONCLUSIONS: Previously reported PAD prevalence
varies depending on clinical presentations, different
screening tools, and the distribution of risks for PAD.
Understanding of and effectively adjusting for these
factors may be helpful to appropriately interpret and
utilize the study results for future research.
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OBJECTIVES: Recent analyses suggest that pulse pres-
sure is an important and independent risk factor for car-
diovascular disease. Accordingly, pulse pressure may also
be an important variable for inclusion in economic analy-
ses of hypertension therapy. We therefore analyzed the
relationship between pulse pressure and cardiovascular
events after adjustment for other risk factors to determine
if pulse pressure is an explanatory variable in the treat-
ment of hypertension. We then evaluated the importance
of pulse pressure as an explanatory variable in the treat-
ment of hypertension.
METHODS: Using multivariate analyses and data from
the Lipid Research Clinic Cohort, we examined the asso-
ciation between speciﬁc blood pressure measures and car-
diovascular death after adjustment for age and other risk
factors. We then compared the goodness of ﬁt (GOF =
[observed events–expected events]2) of various Markov
models to forecast the results of randomized clinical trials
of hypertension therapy using single blood measures or
combinations of measures.
RESULTS: Pulse pressure is a strong univariate risk factor
for coronary and cardiovascular death. Both pulse pres-
sure and diastolic blood pressure were independent (p <
0.05) risk factors with a signiﬁcant negative interaction
between increasing age and diastolic blood pressure and
a positive but non-signiﬁcant pulse pressure x age inter-
action. In Markov model simulations, the model in-
cluding diastolic and pulse pressure better approximated
(GOF = 91) the observed outcomes in ﬁve clinical trials
compared to either systolic, diastolic or pulse pressure
alone (GOF = 208, 375, 706 respectively).
CONCLUSION: Pulse pressure is a signiﬁcant indepen-
dent risk factor for cardiovascular events that increases
in relative importance with increasing age. When pulse
pressure is added to a Markov model with diastolic blood
pressure the results of clinical trials are more accurately
forecasted. Economic analyses of hypertension therapy
may be enhanced by considering blood pressure changes
other than only systolic or diastolic in isolation.
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OBJECTIVES: Cost of treatment for patients with the
same diagnosis can vary enormously due to differences in
comorbidities, practice patterns, and outcomes of care.
We sought to incorporate this variability in a model pro-
jecting the results of clinical trials to community practice.
METHODS: We modeled an episode of care for persons
hospitalized due to acute decompensated heart failure and
urgently treated with either nesiritide or dobutamine.
Patient characteristics and probability of signiﬁcant 
clinical events (cardiac arrest, sustained and non-
sustained ventricular tachycardia, hypotension, vomiting,
readmission and death during follow-up) were based on
pooled analysis of two completed clinical trials. The cost
of a hospital admission was derived from a subset of
records from the 1997 HCUP hospital database for dis-
charges with similar demographic and clinical features (n
= 57,223). Regressions were estimated for equations
explaining 1) hospital length of stay as a function of
patient attributes and speciﬁed clinical events; 2) the cost
of the admission as a function of patient attributes, clin-
ical events and predicted length of stay (LOS). For each
of 5000 simulated patients, the model ﬁrst stochastically
generates new sets of regression parameters using the
means and standard deviations of the original parameter
estimates. Next the model predicts patient demographic
characteristics and incidence of clinical events. The vector
of patient attributes is applied to the vectors of regression
parameters to predict LOS and then cost as a function of
predicted LOS.
RESULTS: This approach preserved distributional char-
acteristics of the original HCUP data (e.g. model pre-
dicted cost of admission vs. HCUP: mean 14,807 vs.
14,666; skew 2.94 vs. 3.16; kurtosis 10.03 vs. 11.43)
while enabling us to differentiate study drugs based on
incidence of clinical events.
CONCLUSIONS: The model yields robust estimates of
cost. Conﬁdence intervals surrounding point estimates
offer decision-makers a reliable basis for assessing 
potential ﬁnancial impact and uncertainty surrounding
adoption of the treatment intervention.
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OBJECTIVES: Economic evaluation requires reliable esti-
mation techniques for hospital costing in multinational
trials. We have developed methods to assign costs to all
hospitalizations by multiplying country-speciﬁc cost 
estimates for a “base” diagnosis by a relative DRG weight
(U.S. DRG weight for the diagnosis in question/DRG
weight for the “base” diagnosis). Our objective was to
assess the validity of calculating country-speciﬁc cost 
estimates computed with U.S.-based DRG weights.
METHODS: Unit costs collected alongside Val-HeFT, a
multinational trial in heart failure, were used to compare
cost estimates provided by local economists with esti-
mates computed using U.S.-based DRG weights. Unit 
cost estimates for 8 diagnoses from 14 countries were
evaluated. We calculated the correlation between the cost
estimates and performed regression analysis to examine
the relationship between them.
RESULTS: When hospitalization for heart failure was
used as the “base” diagnosis, DRG-based cost estimates
were within 35% of the survey estimates for 86% of the
countries for unstable angina, 82% for acute MI, stroke,
and colon cancer. Costs were less well predicted for pul-
monary embolism, coronary stenting, PTCA, and heart
transplant, where only 61.5%, 54.5%, 33.3% and
30.0% of predicted costs were within 35% of survey 
estimates. The DRG-based estimates appeared to over-
estimate costs for procedure-based diagnoses as the costs
were overestimated by 40.3% for stenting, 34.9% for
PTCA, and 77.8% for heart transplant. The Pearson cor-
relation coefﬁcient between the two sets of estimates was
0.682. When excluding heart failure, the regression of
DRG-derived costs on survey-derived costs indicated that
the DRG-based methodology predicted cost estimates
fairly well (adj-R2 = 0.44) (adj-R2 = 0.571 when adjust-
ing for country).
CONCLUSIONS: Estimation of hospital costs based on
U.S. DRG weights appears to be a reasonable solution 
to costing problems in the multinational trial setting.
However, care is required in applying this technique in
studies with high frequencies of surgical procedures.
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Pharmacoeconomic analysis aims to identify and measure
all costs and all outcomes associated with providing a
pharmaceutical product or service. In order to accomplish
this several economic study techniques have been used 
in the pharmacoeconomic literature in various disease
areas.
OBJECTIVES: To determine if there is a relationship
between the type of study (e.g. cost-effectiveness (CEA),
cost-beneﬁt (CBA), cost-minimisation (CMA), cost-utility
analysis (CUA)) used in a pharmacoeconomic analysis
and the disease area being investigated.
METHODS: Five disease areas, as categorised by the
British National Formulary 1 were investigated. A broad
literature search, using MESH terms, was performed
using Medline (PubMed) and abstracts that included full
and partial pharmacoeconomic analyses, from 1966 until
the present day, were considered for review.
RESULTS: 119 abstracts were. No cost-beneﬁt analyses
were found and the most commonly used full economic
techniques were cost-effectiveness and cost-utility analy-
sis; whilst cost analysis was the most commonly used
partial analytic technique. CEA was the preponderant
technique employed in the cardiovascular, respiratory 
and central nervous system disease areas, with contri-
butions of 50% (24/48), 43.48% (10/28) and 45.45%
(5/11) respectively. CUA was preponderant in the
endocrinal disease area, 30.77% (4/13), whilst CEA and
CUA were equally employed in the area of gastrointesti-
nal disease, 33.33% (8/24) and 25.00% (6/24) respec-
tively. Cost-analysis did not dominate any disease area,
and was not found to be preponderant in any speciﬁc
disease area.
CONCLUSION: Although this initial review found that
CEA was the preponderant technique employed in the
cardiovascular, respiratory and central nervous system
disease areas and CUA in the endocrinal disease area, the
relatively small number of papers reviewed cannot allow
one to draw conclusions regarding deﬁnite relation-
ships between disease areas and the type of studies used.
Further analysis of the pharmacoeconomic literature is
required to investigate possible relationships further and
highlight these where they occur.
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OBJECTIVES: To explore the use of sub-group analysis
in economic evaluation and to compare the relevance 
of such analyses to the standard recommendations for
approaching sub-group analysis in clinical studies.
METHODS: The standard pitfalls associated with ad hoc
sub group analyses in clinical evaluation are well known,
and such analyses are generally discouraged. However, in
economics, small differences in effect between sub-groups
can lead to important differences in cost-effectiveness 
for those groups. This suggests that sub-group analysis is
of critical importance for economic evaluation and the
policy decision that such evaluations seek to inform.
However, we must remain mindful of the potential pit-
falls in terms of inappropriate inference, especially when
